Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Emergent BioSolutions

< Previous 1 2 3 Next >
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces Addition to Russell 3000® Index
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions to Participate in Upcoming Investor Conferences
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Reports First Quarter 2025 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces Stock Repurchase Program
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS HKMPY
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
From Emergent BioSolutions
Via GlobeNewswire
Tickers EBS
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.